Climb Bio Inc (CLYM) Stock Forecast & Price Target
Climb Bio Inc · NASDAQ
$12.29-0.50 (-3.91%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Climb Bio Inc, 14 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $12.00 to $35.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $21.33 sits 74% above the current $12.29. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 12 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-1.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Strong Buy
Strong Buy17%
Buy1393%
Hold00%
Sell00%
Strong Sell00%
Based on 14 analysts giving stock ratings to Climb Bio Inc.
As of Jul, 14 of 14 firms rate CLYM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CLYM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.26 – $-0.16 · 8 analysts · +11% YoY
Next period, 8 analysts expect Climb Bio Inc to earn $-0.21 a share (range $-0.26 – $-0.16), versus $-0.19 a year earlier. Full-year consensus is $-0.87, growing to $-1.12 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Climb Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLYM.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$26.00+111.6% to target
Overall win rate
53%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #28
Buy
$35.00+184.8% to target
Overall win rate
52%
+ Follow
#3
Geulah Livshits
Chardan Capital · Rank #100
Buy
$22.00+79.0% to target
Overall win rate
44%
+ Follow
#4
Laura Chico
Wedbush · Rank #122
Buy
$20.00+62.7% to target
Overall win rate
40%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$23.00+87.1% to target
Overall win rate
34%
+ Follow
CLYM stock forecast FAQ
What is CLYM's average 12-month price target?+
The 12 analysts with a live target average $21.33 for Climb Bio Inc over the next 12 months, ranging from a $35.00 high to a $12.00 low.
Is CLYM stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 14 analyst ratings, 14 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CLYM?+
The Street-high target is $35.00 (Guggenheim), and the Street-low is $12.00 (Baird). The average of all 12 active targets is $21.33.
How many Wall Street analysts cover CLYM?+
14 analysts have an active rating on Climb Bio Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering CLYM?+
Among analysts who currently cover CLYM, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $26.00 target.
What is Climb Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.26 – $-0.16) across 8 analysts. Full-year EPS is projected at $-0.87, rising to $-1.12 the following year.
How much revenue is Climb Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CLYM lately?+
As of Jul, 14 of 14 firms rate CLYM a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLYM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
